How long is the hospital stay for CAR T-cell therapy?
The typical hospital stay for CAR T-cell therapy is 10 to 14 days for initial monitoring post-infusion. However, the actual duration is highly variable, ranging from as few as 6 days in outpatient settings to several weeks for patients experiencing severe side effects. The length depends primarily on the specific CAR T product administered, the type of cancer being treated, and the individual patient’s physiological response, particularly regarding cytokine release syndrome (CRS) and neurological toxicities.
Following the one-time infusion, which itself takes only minutes, an inpatient stay is mandatory for close monitoring. This period, often the first 1-2 weeks, is critical for managing immediate and potentially life-threatening reactions. Data from clinical trials and real-world evidence consistently show that a significant portion of patients require this level of acute care. For example, outcomes for different therapies illustrate variance:
| CAR T-Cell Product (Example) | Typical Target Indication | Median/Reported Initial Inpatient Stay Duration | Key Factors Influencing Stay |
|---|
| Axicabtagene ciloleucel | Large B-cell lymphoma | Approximately 7-14 days | High incidence of CRS and neurological events necessitates monitoring. |
| Tisagenlecleucel | B-cell ALL, DLBCL | Around 10 days | Protocol-driven monitoring for safety signals is standard. |
| Idecabtagene vicleucel (Abecma) | Multiple Myeloma | Median 7-10 days | Myeloma patient profile and specific side effect management protocols. |
| Ciltacabtagene autoleucel (Carvykti) | Multiple Myeloma | Can extend beyond 14 days | Often associated with later-onset or prolonged CRS/ICANS. |
The hospitalization period is structured in clear phases. The first 7-14 days post-infusion constitute the acute monitoring phase in the hospital. If significant side effects like high-grade CRS occur, stays can be prolonged for specialized management, including ICU-level care. The requirement to stay within 30-60 minutes of the treatment center for up to 4 weeks post-discharge underscores that the total commitment period is about one month, even if the initial inpatient stay is shorter.
Outpatient or "hybrid" models are changing the landscape. Some accredited treatment centers now offer protocols where stable, low-risk patients receive their infusion and monitoring in an outpatient setting. In these models, the median hospital stay can be reduced significantly, sometimes to as low as 6 days or even eliminated, with daily clinic visits instead. Patient selection for this approach is strict, requiring an optimal health status, strong social support with a committed caregiver, and proximity to the hospital.
Ultimately, preparing for a CAR T-cell therapy journey means planning for a minimum two-week inpatient stay, with flexibility for a longer period. Discussions with your treatment team should focus on your specific therapy regimen, your personal health history, and the center’s capabilities. The core goal of the hospitalization is unwavering: to ensure patient safety during the most critical window of cell expansion and immune activation.
